Study published in PLoS Pathogens suggests new target for treatment and the eventual cure of HIV/AIDS
The SHEA Lectureship award is given annually to recognize the career contributions of a senior investigator in healthcare epidemiology and infection prevention and control.
Expanded partnership between UNC Project-Malawi and Malawi College of Medicine will improve the quality of clinical training in Malawi
UNC-Project Malawi staff train Malawi College of Medicine medical students in order to approve HIV clinical care in Malawi.
The University of North Carolina at Chapel Hill is leading a consortium that will help cultivate the next generation of global health clinicians and scientists, offering a 10-month training fellowship at one of 17 sites in 13 countries in Asia, Africa, and South America.
Lisa Rahangdale, MD, MPH, Assistant Professor, Department of Obstetrics and Gynecology and Director, NC Women’s Hospital Dysplasia Clinic, has received the school’s prestigious James W. Woods Junior Faculty Award.
A new study may help clarify why some people infected with HIV are better able to control the virus. It may also pinpoint a target for treatment during early HIV infection aimed at increasing the supply of certain immune cells in the gut.
Early treatment with antiretroviral therapy reduced the production of latently infected T-cells, a barrier to curing infection
William A. Rutala, PhD, MPH, was honored by the UNC Gillings School of Global Public Health with this prestigious award for alumni at a ceremony preceding the annual Fred T. Foard Jr. Memorial Lecture on April 17.
New research finds that early weaning – stopping breastfeeding before six months – is of little, if any, protective value against HIV transmission nor is it safe for infant survival.
CHAPEL HILL -- A team of researchers at the University of North Carolina at Chapel Hill have successfully flushed latent HIV infection from hiding, with a drug used to treat certain types of lymphoma.
More than 8,000 women participated in the NIH-funded study, which was conducted in part at UNC. The vaccine was partially effective at preventing herpes simplex virus type 1 (HSV-1), but did not protect women from herpes simplex virus type 2 (HSV-2).